Cataract

Cataract original papers on intracameral antibiotics and IOL power, a guideline-based case symposium, and ocular surface sessions headline AAO 2026.

Alessandro Arrigo, MD, describes an early-stage method that uses blue light autofluorescence imaging to grade cataracts objectively. He explains why a reproducible score could help with surgeon selection, IOL power calculation, and retinal image quantification.

Epithelial basement membrane dystrophy can affect premium IOL outcomes.

Bausch + Lomb's SeeLyra femtosecond laser platform, featuring live OCT imaging, has received CE mark approval for cataract, LASIK, and corneal procedures in Europe.

Ahead of the 44th ESCRS Congress in London, a look at the presbyopia-correcting IOL, glaucoma and dry eye disease research on this year's scientific programme.

Cataract safety, Glaucoma drugs and MIGS, plus Artificial Intelligence debates and retina breakthroughs—key FDA moves and trial updates in ophthalmology.

Antibiotic injection reduced endophthalmitis risk vs topical drops after cataract surgery, meta-analysis found.

Alice Epitropoulos, MD, shares cases of Demodex blepharitis and reflects on how lotilaner has changed treatment before ocular surgery.

Approach centers on pressure-free messaging and optometric education

Waste, cost, and carbon are converging to reshape how cataract centers choose instruments.

In part 2 of a 2-part article, Arun C. Gulani, MD, walks through the 4 patient types of the Gulani classification of refractive lens exchange, from primary vision enhancement to staged vision engineering, and explains why outcomes depend on treating the eye as a complete optical system rather than on the implant alone.

Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.

Arun C. Gulani, MD, introduces the Gulani classification of refractive lens exchange, a 4-type framework for individualizing premium IOL selection and surgical strategy around each eye's visual potential rather than its diagnosis.

The multicenter study is evaluating ZOC2017217, a lanosterol-derived investigational eye drop, ahead of a planned phase 3 trial.

Length and width, not thickness, emerge as key drivers of higher-order aberrations.

A midyear recap of the cataract-related news Ophthalmology Times has covered in 2026